Studies demonstrated that overexpression of ACSL3 was detected in various malignancies such as hepatoma, prostate cancer, and NSCLC [25, 26, 27], revealing ACSL3 as a promising protective factor of prognosis in patients with cancer. Here, ACSL3 is linked to prostate cancer.